key: cord-0754876-70jg65o2 authors: Zhang, J.; Qu, X. title: Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals date: 2020-06-14 journal: nan DOI: 10.1101/2020.06.12.20129460 sha: 57be2b8cc4b861cd2dbda6bb731990563f3932d5 doc_id: 754876 cord_uid: 70jg65o2 Seroconversion appeared early after COVID-19 onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited cross-neutralization against SARS-CoV (76.12%), MERS-CoV (17.91%), or both (10.45%). Interestingly, individuals recovered from severe disease (severe group) had nAbs with binding and neutralization titers higher than non-severe group. Severe group appeared a rapid increase of lymphocytes and a high proportion of circulating CXCR3+ Tfh cells. Interestingly, the later were spike-specific and positively correlated with SARS-CoV-2 nAb titers. All subjects had no autoimmunity. Our findings provide novel insights into nAb responses in COVID-19 convalescents and facilitate treatment and vaccine development for SARS-CoV-2 infection. Coronavirus Disease 2019 (COVID- 19) , an emerging disease caused by SARS-CoV-2 infection 1-3 , has globally spread causing >4.5 million infections and 0.3 million deaths 4 . Symptoms of COVID-19 range from asymptomatic, mild, moderate to severe 5, 6 . No specific drug and vaccine available for COVID-19, and treatments are primarily the supportive cares. Convalescent sera have proven to improve clinical presentation and reduce mortality of critical patients 7, 8 . Serum SARS-CoV-2-specific IgM 9-12 and in most of patients IgG [13] [14] [15] were detectable during 4-to-14 days after symptom onset, though T and B cells decreased dramatically at early acute phase of infection. Few studies reported that neutralizing antibody (nAb) responses to viral spike protein were variable in recovered COVID-19 individuals 1, 16, 17 . Monoclonal nAbs have been isolated from COVID-19 convalescents and are facilitating clinical trials of antibody therapy and vaccine development 18, 19 . However, nAb responses in COVID-19 convalescents are largely unclear, in respect to neutralizing activity, avidity, and cross-neutralization with other coronaviruses. Although lymphocytes play essential role in antibody initiation and maturation, the association of T cell populations with SARS-CoV-2-specific nAb responses remains unknown. In this study, we recruited 67 recovered COVID-19 individuals. Blood was drawn on day 28 after discharge. The baseline clinical characteristics and laboratory findings on admission was retrospectively analyzed (Extend Data Tables 1 and 2 ). The binding titer and avidity of serum IgG against S1 and S2 subunits of SARS-CoV-2 spike antigen were examined by ELISA assays (Methods, Online content). All recovered patients had robust anti-S1 (median, 4.61; IQR, 4.01-4.61) and anti-S2 (median, 4.91; IQR, 4.61-5.52) IgG All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint antibodies, and anti-S2 titers were significantly higher than anti-S1 (p<0.001) ( Fig. 1a and Extend Data Table 3 ). All 67 subjects showed avidity index to S1 (median, 44.5; IQR, 34.5-51.75) and S2 (median, 58; IQR, 49-67) antigens (3 samples with marginal binding), and avidity indices to S2 were higher (p<0.001) (Fig.1b) , in consistence with the endpoint titers (Fig. 1a ). Next, we tested the antibody binding to spike proteins from both SARS-CoV and MERS-CoV. The results showed that 38.81% (26/67) and 73.13% (49/67) had cross-reactions with S1 of SARS-CoV and S2 of MERS-CoV, but not with S1 of MERS-CoV (Fig. 1c) . No binding to SARS-CoV S1, and only 6.67%, 1.67% sera from 60 healthy controls showed binding to MERS-CoV S1 and S2, respectively (Extend Data Table 4 ). We did not test S2 of SARS-CoV due to no qualified antigen available. To determine the neutralizing and cross-neutralizing activities, we developed SARS-CoV-2 spike-based pesudovirus for neutralization experiments, in parallel with previously developed SARS-CoV and MERS-CoV pesudoviruses 20 . Of 67 individuals, 65 (97.01%) elicited nAbs neutralizing SARS-CoV-2 pesudovirus (median ID 50 , 2.75; IQR 2.34-3.08) ( Fig. 1d and e) , and neutralization titers were positively correlated with the endpoint titers of SARS-CoV-2 S1-and S2-specific antibodies (Extend Data Fig. 1a c). Interestingly, 51 (76.12%, 65.67% plus 10.45%) sera showed cross-neutralization with SARS-CoV, 12 (17.91%, 7.46% plus 10.45%) with MERS-CoV, and 7 (10.45%) with both ( Fig. 1f) . Sera with and without cross-neutralization activity had no differences in neutralization titers for SARS-CoV-S2 (Extend Data Fig. 2a and b) , but crossneutralization activity for SARS-CoV and MERS-CoV were significantly weaker than for SARS-CoV-2 (Extend Data Fig. 2c-e) . These findings demonstrate that majority of recovered COVID-19 individuals elicited and maintained robust nAb responses to SARS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint CoV-2. Some antibodies had cross-binding and neutralizing activities against SARS-CoV and/or MERS-CoV. No autoimmune antibodies were detected in recovered COVID-19 individuals (Extend Data Table 5 ). Patients with severe and mild COVID-19 symptoms were reported with distinct clinical and immunological presentations 9-11 . Here, we categorized all 67 recovered individuals into "severe" (17/67) and "non-severe" (50/67) groups, according to the severity of disease that patients had suffered (Extend Data Table 1 ). Compared to non-severe group, severe group exhibited higher titers of anti-S1 (p=0.012) and anti-S2 antibodies (p=0.011) ( Fig. 2a) and higher neutralization titers (p=0.001) (Fig. 2b ), but no difference for binding avidity (Fig. 2c ). Next, we analyzed the factors that may associate with nAbs responses and found that nAb response was correlated with the severity of disease (Table 1) , though older age (p<0.001), longer course of disease (p=0.007), more comorbidities (p=0.044), and underlying diseases (p<0.001) were higher in severe group (Extend Data Table 1 ). Further analysis of lymphocyte counts at five time-points, including admission, midcourse, discharge, day 14 and 28 after discharge revealed that majority 16/17 (94.12%) of severe group exhibited lower lymphocyte count on admission, in line with a recent report 5 , while non-severe group that was at the bottom line of normal range (1.2-3.5×10 9 /L) (Fig. 2d) . Unlike slow increase in non-severe group, lymphocyte counts of severe group increased gradually during hospitalization and restored to normal on discharge (median, from 0.65 to 2.28×10 9 /L), maintained at this level for two weeks, then unexpectedly rebound from day 14 to 28 after discharge, crossing and having mean value higher than that of non-severe group (p=0.08) (Fig. 2d) . Severe group had higher fold All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 8 change of lymphocytes, related to admission respectively, at all later time points (p<0.01) (Fig. 2e ). Next, we investigated whether the increased lymphocytes contributed to nAbs production. Circulating T follicular helper (Tfh) cells, counterparts of germinal center Tfh cells 21 , are important for maturation and antibody production of T-dependent B cells 22,23 . We found that severe and non-severe groups had no difference in circulating Tfh frequency (Fig. 3a) , however, CXCR3 + Tfh cells (p=0.016) and CXCR3 + /CXCR3 -Tfh cells (p=0.014) were higher in severe group ( Fig. 3b-d) . Interestingly, nAb titers were positively correlated with CXCR3 + Tfh frequency (r=0.486, p=0.012) and the ratio of CXCR3 + /CXCR3 -Tfh cells (r=0.467, p=0.016) ( Fig. 3e and f), but not with total Tfh (r=-0.004, p=0.985) and CXCR3 -Tfh cells (r=-0.435, p=0.025) ( Fig. 3g and h) . These findings indicate that CXCR3 + Tfh cells may play an important role in supporting or maintaining nAb responses in recovered COVID-19 individuals. Then, we proceeded to examine whether these CXCR3 + Tfh cells were SARS-CoV-2 spike-specific. We stimulated PBMCs from convalescents with both S1 and S2 (S1+S2) of SARS-CoV-2 spike and identified spike(S1+S2)-specific proliferation of CD25 + OX40 + CXCR3 + Tfh cells (Fig. 3i) . We previously found a positive correlation between CXCR3 + Tfh cells with HCV nAb titer 24 . Similarly, CXCR3 + ICOS + CXCR5 + CD4 + T cells 25 and circulating Th1-biased helper cells 26 were positively associated with influenza virus-and HIVspecific antibody responses, respectively. Together, we concluded that CXCR3 + Tfh cellcontribute to initiate and/or maintain nAbs in recovered COVID-19 individuals. We have systematically investigated antibody responses in recovered COVID-19 individuals. Of 67 subjects, 97.01% (65/67) elicited nAbs potently neutralized SARS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 1 0 by 25% SARS-CoV srea 31 . Existence of cross-neutralizing antibodies offers a possibility to isolate or develop antibodies with neutralizing activity across different coronaviruses. It is surprising that individuals recovered from severe COVID-19 elicited and maintained higher antibody and neutralization titers than non-severe group (Fig. 2) , and the nAb titers positively correlated with severity of disease other than other factors (Table 1, Extend Data Table 1 ). Similar to what seen for recovered MERS-CoV patients, levels of nAbs positively associated with days in ICU, viral shedding, and ventilation need, several characteristics of critical conditions 32 . We found that SARS-CoV-2 convalescents exhibited low lymphocyte count during the course of disease, but with an accelerated increase, followed by a rebound after discharge ( Fig. 2d-e) . Rapidly increased lymphocyte counts may be responsible for the high levels of nAb. In recovered MERS-CoV and SARS-CoV-2 patients, nAbs were correlated with antigen-specific CD4 + T cells 16, 32 , and nAb responses were more stable and longer in recovered severe MERS-CoV patients 33 . Importantly, we found that levels of CXCR3 + Tfh cells was significantly higher in recovered severe group than in non-severe group, correlated with nAb responses, and importantly were spike-specific ( Fig. 2e-i) . Correlations of CXCR3 + Tfh cells with nAb responses also exists in other virus infections, such as HCV 24 and HIV 26 . Study on one non-severe COVID-19 patient showed that PD-1 + ICOS + Tfh cells progressively increased from day 7 after onset of illness 34 . Taken together, circulating CXCR3-biased Tfh cells increased rapidly in severe COVID-19 patients play a critical role in eliciting spike-specific antibodies, with neutralizing activity for SARS-CoV-2 and, to a less extent, for SARS-CoV and MERS-CoV. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . In conclusion, we demonstrated that majority of recovered COVID-19 individuals elicited and maintained robust nAb responses, of which some can cross-neutralize SARS-CoV and/or MERS-CoV. The nAb responses are positively correlated with severity of disease and with spike-specific circulating CXCR3 + Tfh cells, which were more rapidly populated in recovered severe patients. Beyond this cross-sectional study, the longevity and affinity maturation of nAbs warrant future investigations. Our findings provide important evidence on humoral responses to SARS-CoV-2 infection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . IgG antibodies from recovered COVID-19 individuals (n=67) determined by binding to S1 and S2 subunits of SARS-CoV-2 spike protein; Binding to S2 was significantly higher than binding to S1. b, Avidity index of serum IgG antibody to S1 and S2 antigens of SARS-CoV-2 (n=64); S2 showed higher avidity. c, Percentage of COVID-19 convalescent sera cross-binding with S1 of SARS-CoV spike protein and S1 and S2 of MERS-CoV spike (total, n=67). d, Percentage of sera with neutralizing IgG antibody All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . against SARS-CoV-2 pseudovirus particles (64/67, n=67). e, Neutralizing titer of sera IgG antibody (n=67) against SARS-CoV-2 pseudovirus particles (ID 50 , Log 10 ). f, CoV and MERS-CoV; plus "+" and minus "-" stand for positive and negative neutralization, respectively. Endpoint titer and neutralization titer were logarithmic transformed (a and e). Mann-Whitney U test was used to compare difference between two groups (a and b), and adjusted p value <0.05 was considered significant difference between groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . a, Endpoint titers of serum IgG antibodies specific to S1 and S2 of SARS-CoV-2 spike for severe (n=17) and non-severe (n=50) groups; severe group was significantly higher than non-severe group. b, Neutralization titers of sera, from severe (n=17) and non-severe (n=50) groups, against SARS-CoV-2 pesudovirues; Titers of severe group was higher than non-severe group. c, Avidity of serum IgG antibodies to S1 and S2 of SARS-CoV-2 for severe (n=16) and non-severe groups (n=48); no significant difference between two groups. d-e, Kinetics (d) and fold change (e) of lymphocyte count in severe (red line) and non-severe (blue line) groups; lymphocyte counts of severe group increased faster than non-severe group during the course of disease and after discharge; patient number Mann-Whitney U test was used to compared difference between two groups (a-e), and p value <0.05 was considered significant difference between groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . (n=5) were stimulated with both S1 and S2 proteins (S1+S2) for 24 hours, antigenspecific Tfh (OX40 + CD25 + CXCR3 + Tfh) cells were analyzed by flow cytometry. Neutralization titers were logarithmic transformed (e-h). Mann-Whitney U test was used to compared difference between two groups (a-d), Paired t test was used to compared difference between two groups (i). Spearman's rank correlation coefficient was used to describe the relationship between neutralization titers and frequencies of Tfh cells and subsets (e-h). p value <0.05 was considered significant difference between groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 2 0 Tables Table 1 Data expressed as Odds ratios (OR) and 95% two-sided confidence interval (95% CI). Univariate and Multivariable Binary Logistic Regression models were used to evaluate the influence factors for neutralizing antibody. The median of cutoff dependent variable value (ID 50 , Log 10 ) for neutralization were set at 2.41, thus the estimated probability of <2.41 was classified as low neutralization ability group, and a probability of >2.41 was classified as high neutralization ability group. All of covariates were classified by median and changed to two categories of variables for Logistic Regression analysis. Course of disease was defined as the duration (days) from disease onset to discharge. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 2 1 Total 67 recovered COVID-19 patients were enrolled in this study, and diagnosis of COVID-19 was performed according to WHO interim guidance. All of patients came to outpatient showed fever or respiratory symptoms. Chest computed tomography (CT) scans identified abnormal pulmonary nodules, and SARS-CoV-2 infection was further Of 67 patients, 17 were categorized in severe conditions, and 50 were in mild to moderate symptoms (refer to as non-severe in this study). The medical history and the results of physical, hematological, biochemical, radiological, and microbiological analyses were retrospectively evaluated and analyzed. Peripheral blood of the recovered individuals was collected on day 28 after discharge, corresponding to 44 to 52 days after symptom onset. Peripheral blood mononuclear cells (PBMCs) and serum were isolated and frozen in liquid nitrogen at -80°C ultra-low temperature freezers, respectively. The endpoint titer of antibody was determined by measuring the binding index of serum with S1 and S2 subunits of SARS-CoV-2 spike protein using enzyme linked immunosorbent assay (ELISA). In brief, 96-well plates (Corning, NY, USA) were coated with 20 ng/well S1 or S2 subunit proteins in PBS overnight at 4°C. Plates were washed with 0.05% Tween-20 in PBS (PBS-T) for 5 times and then blocked with blocking buffer All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 2 2 (2% FBS and 2% BSA in PBS-T) for 30 minutes. Two-fold serial dilutions, started from 1:20 dilution, were added to the plate in triplicate (100 µl/well) and incubated for 1 hour at room temperature. Spike subunits S1-and S2-specific antibodies were detected by using horseradish peroxidase (HRP)-conjugated anti-human IgG and 3,3',5,5'tetramethylbenzidine substrate (Thermo Fisher Scientific, Waltham, MA, USA). Healthy sera were used as negative controls, and monoclonal antibody specific for the receptor binding domain (RBD) of SARS-CoV-2 spike protein (anti-RBD/SARS-CoV-2; made in the lab, unpublished data) was used as positive control. Optical density at 450 nm (OD450) was acquired for each reaction, and the OD450 being 3-fold above the cutoff-OD450 value was considered to be positive. Serum cross-reactivity with S1 of SARS-CoV as well as with both S1 and S2 of MERS-CoV were examined using an optimized serum dilution (1:1000). All of proteins (S1 and S2 of SARS-CoV-2; S1 of SARS-CoV; S1 and S2 of MERS-CoV) were purchased (Sino Biological, China). IgG antibody avidity with S1 and S2 subunits from SARS-CoV-2 were measured by a modified 2-step approach described elsewhere 1,2 . In the first step, serum dilutions were optimized to have an OD450 value between 0.5 and 1.5, so that it could ensure a linear measurement of avidity in next step. The second step was an ELISA assay but included an elution procedure of 1M NaSCN. The avidity index of antibody was calculated as OD NaSCN 1M/OD NaSCN 0M × 100%. Neutralizing activity of sera was determined by the reduction in luciferase expression, as described previously for the HIV pseudovirus neutralization assay 3 . The 50% inhibitory All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Naïve Huh7 cells were added to each well and incubated in 5% CO 2 at 37°C for 24 hours. The luminescence was measured, and the ID 50 values were calculated with non-linear regression, i.e. log (inhibitor) vs. response (four parameters), using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). Cross-neutralization with SARS-CoV and MERS-CoV were determined using same methods. Two milliliters of blood were collected from the participants using EDTA anticoagulation tubes (BD Biosciences, Franklin Lake, NJ, USA), and sera were immediately isolated by All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 2 5 Cryopreserved PBMCs were thawed and cultured in complete RPMI1640 medium in 5% CO2 at 37°C incubator overnight. Cells were stimulated with SARS-CoV-2 spike protein (S1 plus S2) (5μg/mL) or negative control BSA (5μg/mL) (Sigma-Aldrich, St. Louis, MO, USA) in 5% CO2 at 37°C for 24 hours. PBMCs from healthy controls were included in parallel as controls. Circulating Tfh (cTfh) cells were gated as live CD4 + PD-1 + CXCR5 + T cells. PE-Cy™5 mouse anti-human CD25 (M-A251) (BD Biosciences) and APC mouse anti-human OX40 (ACT35) (BioLegend) were used to define antigen-specific (CD25 + OX40 + ) Tfh cell responses after stimulation as described previously 4, 5 . Baseline clinical characteristics data were non normal distribution, so continuous variables were expressed as median and Interquartile Range (IQR). Rank variables was expressed as constituent ratio. Mann-Whitney U test and χ ² or Fisher's Exact tests were used in the comparison of two different groups. Paired Sample t test was used to compare the antigen-specific Tfh cells before and after the stimulation with S1 and S2 proteins. Kruskal-Wallis test was used for the comparison of multiple groups, and Dunn's multiple comparisons test was used between two groups. Spearman's Rank Correlation Coefficient was used to measure the correlation between two variables of Tfh cells, neutralization antibodies, and binding avidity. Univariate and Multivariable Binary Logistic Regression model was used to rank the factors potential associations with nAb responses. Odds ratios (ORs) and 95% two-sided confidence interval (95% CI) were generalized by equation models to describe the factors contributing to nAb responses. Analyses of the data were done by SPSS version 26 and GraphPad Prism version 8.0. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. Correlation analysis was performed, using Spearman's rank coefficient of correlation, to identify the strength of relationships between neutralization titers of serum antibodies against SARS-CoV-2 pesudovirus and the endpoint titers (binding activity) of antibodies binding to S1 and S2 subunits of SARS-CoV-2. Correlation between S1-and S2-specific endpoint titers of serum antibodies (a), sera neutralization titers and S1-specific endpoint titers (b), and sera neutralization titers and S2-specific endpoint titers (c); Positive correlations existed between S1-and S2-specific endpoint titers as well as between neutralization and S1-or S2-specific endpoint titers. p value <0.05 was considered to be significantly different between groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 2 9 individual COVID-19 convalescent serum; cross-neutralization titers for SARS-CoV or MERS-CoV were lower than that for SARS-CoV-2. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. Representative flow cytometry plots for the spike antigen-specific CXCR3 + Tfh cell (CD25 + OX40 + CXCR3 + Tfh cells ) responses from healthy control and recovered COVID-19 individuals. Gating was based on the mean fluorescence intensity "minus one" (FMO). PBMCs were stimulated with S1 plus S2 subunits (5μg/mL) of SARS-CoV-2 spike protein in 5% CO2 at 37°C for 24 hours. Cells stimulated with BSA (5μg/mL) were negative control. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 3 3 3 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint 3 5 P T 3 7 2 5 6 0 8 1 9 2 0 6 6 9 0 --+ 3 3 2 4 8 6 < 3 0 P T 3 8 1 2 8 0 5 1 2 0 4 2 6 9 ---< 3 0 < 3 0 < 3 0 P T 3 9 5 1 2 0 6 5 5 3 6 0 5 8 9 5 --+ 3 4 4 1 3 6 < 3 0 P T 4 0 1 0 2 4 0 2 0 4 8 0 5 2 6 9 --+ 3 1 6 6 8 < 3 P T 5 6 4 0 9 6 0 3 2 7 6 8 0 2 3 3 7 --+ 1 4 3 3 4 2 0 2 7 2 P T 5 7 2 5 6 0 4 0 9 6 0 4 9 5 1 --+ 3 9 5 2 4 8 3 4 P T 5 8 5 1 2 0 2 0 4 8 0 5 6 6 1 ---1 1 3 4 4 0 < 3 0 P T 5 9 1 0 2 4 0 1 6 3 8 4 0 5 6 5 3 --+ 1 3 8 9 4 1 6 < 3 0 P T 6 0 5 1 2 0 5 1 2 0 6 6 6 5 ---9 2 < 3 0 < 3 0 P T 6 1 8 1 9 2 0 8 1 9 2 0 4 3 6 7 ---8 3 7 4 2 0 < 3 0 P T 6 2 1 0 2 4 0 8 1 9 2 0 5 6 6 2 --+ 3 3 5 4 7 < 3 0 P T 6 3 5 1 2 0 8 1 9 2 0 4 2 4 4 --+ 1 8 4 6 2 < 3 0 P T 6 4 5 1 2 0 4 0 9 6 0 4 8 7 1 ---1 3 9 4 4 < 3 0 P T 6 5 1 0 2 4 0 8 1 9 2 0 3 6 4 7 --+ 8 8 5 9 < 3 0 P T 6 6 1 0 2 4 0 8 1 9 2 0 5 0 6 6 ---1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 14, 2020. . https://doi.org/10.1101/2020.06.12.20129460 doi: medRxiv preprint Extend Data │ Table 4 Healthy control SARS-CoV S1 MERS-CoV S1 MERS-CoV S2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. T 1 2 1 : 2 0 3 7 -----------P T 1 3 < 1 : 2 0 8 8 ------+ ----P T 1 4 < 1 : 2 0 2 0 6 -----------P T 1 5 < 1 : 2 0 3 1 -----------P T 1 6 < 1 : 2 0 1 7 0 -----------P T 1 7 < 1 : 2 0 2 3 -----------P T 1 8 < 1 : 2 0 6 4 ------+ ----P T 1 9 < 1 : 2 0 3 5 -----------P T 2 0 < 1 : 2 0 8 4 -----------P T 2 1 < 1 : 2 0 5 0 -----------P T 2 2 < 1 : 2 0 3 6 -----------P T 2 3 < 1 : 2 0 4 6 -----------P T 2 4 < 1 : 2 0 1 5 -----------P T 2 5 1 : 4 0 2 8 -----------P T 2 6 < 1 : 2 0 4 0 -----------P T 2 7 < 1 : 2 0 4 3 -------+ ---P T 2 8 < 1 : 2 0 3 3 -----------P T 2 9 < 1 : 2 0 3 9 --------- --All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. P T 3 0 < 1 : 2 0 4 4 -----------P T 3 1 1 : 2 0 6 3 -----------P T 3 2 < 1 : 2 0 5 1 -----------P T 3 3 < 1 : 2 0 3 0 -----------P T 3 4 1 : 8 0 5 1 ----+ ---- All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered_patient cohort and their implications A Novel Coronavirus from Patients with Pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin Clinical Characteristics of Coronavirus Disease Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients A serological assay to detect SARS-CoV-2 seroconversion in humans Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Antibody responses to SARS-CoV-2 in patients with COVID-19 Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells Activation of Peripheral T Follicular Helper Cells During Acute Dengue Virus Infection We thank all of the participants. The authors declare no competing interests.